Profluent
Profluent is seeking a detail-oriented individual to join the Technology Development team and contribute to the development and application of high-throughput workflows for genome editing. The role involves conceptualizing, developing, and scaling arrayed assays for gene editing in mammalian cells while collaborating internally to improve novel and existing assays. This position operates at the intersection of biology, automation, and data to advance cutting-edge research and drive impactful projects.
Headquarters
Emeryville, California, United States
Company Size
11-50 employees
Founded
2022
Profluent is an AI-driven protein design company that uses generative machine learning to author novel proteins, either inspired by natural scaffolds or designed from scratch. Its flagship achievement is OpenCRISPR, the world's first AI-designed gene editor, and its platform enables applications across therapeutics, industrial enzymes, and beyond. Profluent partners with organizations such as Eli Lilly to translate AI-authored protein designs into real-world solutions across medicine, agriculture, and other industries.
Profluent Raises $106M to Scale Frontier AI Models for Programmable Biology
Nov 19, 2025
Profluent Secures $106M Funding to Enhance AI-Driven Biology Solutions
Nov 25, 2025
AI for crop engineering: Corteva, Profluent Bio partner to develop gene editing tools
Oct 7, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Profluent.
12% below the average for this role
AI biotech Profluent closes $106M raise with Jeff Bezos’ support
Nov 19, 2025